D
Denis Guyotat
Researcher at French Institute of Health and Medical Research
Publications - 55
Citations - 2295
Denis Guyotat is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Myeloid leukemia & Transplantation. The author has an hindex of 22, co-authored 55 publications receiving 2235 citations.
Papers
More filters
Journal ArticleDOI
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
François Guilhot,Claude Chastang,Mauricette Michallet,A. Guerci,Jean Luc Harousseau,Frédéric Maloisel,R. Bouabdallah,Denis Guyotat,Cheron N,Franck E. Nicolini,JF Abgrall,Tanzer J +11 more
TL;DR: The combination of interferon and cytarabine, as compared withinterferon alone, increases the rate of major cytogenetic response and prolongs survival in patients with the chronic phase of chronic myelogenous leukemia.
Journal ArticleDOI
Comparison of Autologous Bone Marrow Transplantation and Intensive Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia
Jean-Luc Harousseau,Jean-Yves Cahn,Bernard Pignon,Francis Witz,Noel Milpied,Martine Delain,Bruno Lioure,Thierry Lamy,Bernard Desablens,François Guilhot,Denis Caillot,JF Abgrall,Sylvie François,Jean Briere,Denis Guyotat,Philippe Casassus,Bruno Audhuy,Zéra Tellier,Patrick Hurteloup,Patrick Hervé +19 more
TL;DR: Three intensive consolidation strategies are currently proposed to younger adults with acute myeloid leukemia (AML) in first complete remission (CR): allogeneic or autologous bone marrow transplantation (BMT) and intensive consolidation chemotherapy (ICC).
Journal ArticleDOI
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia : a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM)
Marie-Cécile Michallet,Xavier Thomas,J P Vernant,M Kuentz,Gérard Socié,H. Esperou-Bourdeau,Noel-Jean Milpied,Didier Blaise,Bernard Rio,Josy Reiffers,J P Jouet,J. Y. Cahn,J. H. Bourhis,Bruno Lioure,Michel Leporrier,Jean-Jacques Sotto,G Souillet,Laurent Sutton,Pierre Bordigoni,Francois Dreyfus,H. Tilly,N. Gratecos,M. Attal,P. Y. Leprise,François Demeocq,G. Michel,Agnès Buzyn,B Delmas-Marsalet,F. Bernaudin,Norbert Ifrah,A Sadoun,Denis Guyotat,M Cavazzana-Cavo,Denis Caillot,T de Revel,J P Vannier,André Baruchel,Nathalie Fegueux,M L Tanguy,Anne Thiebaut,A Belhabri,Eric Archimbaud +41 more
TL;DR: The results of this study suggest that the graft-versus-leukemia effect is important in advanced AML and that new HSCT modalities are needed for some patients with this indication.
Journal ArticleDOI
Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM)
Mauricette Michallet,M L Tanguy,Gérard Socié,A Thiébaut,A Belhabri,Noel-Jean Milpied,Josy Reiffers,M Kuentz,Jean-Yves Cahn,Didier Blaise,François Demeocq,Jean-Pierre Jouet,Anne-Sophie Michallet,Norbert Ifrah,Etienne Vilmer,Lysiane Molina,G. Michel,Bruno Lioure,M Cavazzana-Calvo,Jose-Luis Pico,A. Sadoun,Denis Guyotat,Michel Attal,H. Cure,Pierre Bordigoni,L. Sutton,A Buzyn-Veil,M Tilly,N Keoirruer,N Feguex +29 more
TL;DR: The best candidates for a second transplant are likely to be patients with acute leukaemia in remission before transplant, in whom the HLA‐identical donor was female and who relapsed more than 1 year after the first transplant.
Journal ArticleDOI
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation
M. Mohty,Karin Bilger,Eric Jourdan,M Kuentz,Mauricette Michallet,J. H. Bourhis,Noel-Jean Milpied,Laurent Sutton,J P Jouet,M. Attal,Pierre Bordigoni,J.Y. Cahn,A Sadoun,Norbert Ifrah,Denis Guyotat,C. Faucher,Nathalie Fegueux,Josy Reiffers,D. Maraninchi,Didier Blaise +19 more
TL;DR: Efforts to accelerate engraftment by increasing CD34+ cell dose must be counterbalanced with the risk of detrimental cGVHD, as this has not translated into a difference in relapse.